Tarceva erlotinib regulatory update

ROCZ submitted an MAA to the EMEA for Tarceva as monotherapy to treat advanced non-small cell lung cancer (NSCLC) patients for whom chemotherapy has failed. OSIP completed its submission of an NDA for...